YOU SEARCHED BY...
SEARCH BY...
Country
- Australia(1)
- Belgium(1)
- Canada(4)
- China(4)
- France(1)
- Germany(8)
- India(3)
- South Korea(2)
- Spain(2)
- Switzerland(2)
- The Netherlands(1)
- Turkey(1)
- United Kingdom(2)
- United States(54)
- Vietnam(1)
Contract Service Directory
Samsung Biologics
Company Headquarters
300, Songdo bio-daero, Yeonsu-gu, Incheon, South Korea
송도동, 연수구
인천광역시 406-840
South Korea
Company Description
Samsung Biologics is a fully integrated CDMO offering contract development, manufacturing, and analytical services. With proven regulatory approvals, the largest capacity at a single site, and the fastest throughput, we can support every stage of the process while meeting the evolving needs of biopharmaceutical companies worldwide.
Contract Service Directory
- Analytical Laboratory Services
- Bioanalytical Services
- Biological Testing
- Biologics Manufacturing
- Biologics Process Development
- Cell Culture Media Development
- Cell Line Construction & Development
- Chemical Analysis
- Contract Development and Manufacturing Organization (CDMO)
- Contract Manufacturing
- Encapsulation
- Fermentation
- Filling, Vial
- Formulation Development
- Formulation Services
- Mammalian Cell Culture
- Manufacturing, Aseptic Fill/Finish
- Manufacturing, Biologics
- Manufacturing, Clinical Trials Supply
- Manufacturing, Vaccines
- Process Development/Scale-Up Services
- Process R&D
- Process Validation Studies
- Project Management
- Purification
- QA/QC
- Quality Control Testing
- R&D Services
- Raw Materials Analysis
- Scale-Up
- Technology Transfer
- Validation, Equipment Cleaning
- Validation, Filtration
- Validation, Manufacturing
- Validation, Services
Content From Samsung Biologics
-
Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience
Through digital transformation, Samsung Biologics is innovating how they connect with clients, regulatory bodies and industry professionals.Sponsored Content Released on 12.22.2020
Related Content
-
Breaking News | Industry News
Samsung Biologics to Participate in Frontier 1.5D Initiative
Will develop a climate risk management model as part of 2050 Carbon Neutral Strategy in response to the challenges associated with climate change.09.14.21
-
Analytical Services | Bioanalytical Services
Putting Laboratory Suppliers to the Test in the COVID Era – and Beyond
Build resiliency into analytical methods through careful consideration of chromatography partners.Hazel Dickson, PhD, Marketing Manager, Chemistry Group, Waters Corporation 09.09.21
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
Samsung Biologics Signs Agreement with Kahr Medical
Will support Kahr’s drug candidate DSP502, a TIGITxPD1 fusion protein.Charles Sternberg, Assistant Editor 06.03.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Parenterals
Samsung Biologics Expands Vaccine Manufacturing Capabilities
To add mRNA vaccine drug substance manufacturing suite to expand portfolio of services.Tim Wright, Editor, Contract Pharma 06.01.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Samsung Biologics, TG Therapeutics Expand Manufacturing Collaboration
Expands existing contract manufacturing deal to further enable global manufacture of ublituximab.Tim Wright, Editor, Contract Pharma 04.27.21
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Collaborations & Alliances | Facilities | Industry News
Samsung Bioepis Opens New Headquarters
The 52,000-square-foot campus to become the hub of Samsung Bioepis’ drive for accelerated development of next-gen biologic medicines.Tim Wright, Editor, Contract Pharma 01.25.21
-
Analytical Services | Biologics, Proteins, Vaccines | Clinical Trial Materials | Laboratory Testing
Samsung Biologics Continues to Leverage Digitalization to Optimize Client Experience
Through digital transformation, Samsung Biologics is innovating how they connect with clients, regulatory bodies and industry professionals.
-
Bio News | Breaking News | Industry News | Promotions & Moves
Samsung Biologics Names John Rim as President and CEO
Prior to being named chief executive, Rim was executive vice president at the Korea-based CDMO for the past three years.Contract Pharma Staff 12.16.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News | Information Technology | QA/QC
Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
CDMO is managing quality processes and content for greater visibility and compliance across global manufacturing.Contract Pharma Staff 12.16.20
-
Breaking News | Facilities | Industry News | Information Technology
Samsung Biologics Launches Virtual Showroom
Provides key features and real-time construction updates of its recently announced Plant 4.Contract Pharma Staff 12.07.20
-
Bio News | Breaking News | Facilities | Industry News
Samsung Biologics Breaks Ground on 'Super Plant'
When completed, the CDMO says it will be the world's largest bio-manufacturing facility.Contract Pharma Staff 11.24.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
Samsung Biologics Signs Deal with Kanaph Therapeutics
To develop treatment for retinal diseases.Contract Pharma Staff 09.24.20
-
Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Samsung Biologics and AstraZeneca Ink Manufacturing Deal
Partnership for global supply could be worth more than $545 million.Contract Pharma Staff 09.22.20
-
Breaking News | cGMP Manufacture | Collaborations & Alliances
PharmAbcine Partners with Samsung Biologics for PMC-403
The antibody is expected to enter a global ophthalmological clinical trial in 2022.Contract Pharma Staff 09.21.20
-
Bio News | Breaking News | Facilities | Industry News
Samsung Biologics Expands Footprint
Will break ground on its fourth plant this year, adding 256KL of capacity.Contract Pharma Staff 08.12.20
-
Bio News | Breaking News | Facilities | Industry News
Samsung Biologics Expands Manufacturing Facility in Incheon
Plans to add a flexible filling line and two additional lyophilizer units.Contract Pharma Staff 07.27.20
-
Bio News | Breaking News | Collaborations & Alliances | Industry News
Samsung Biologics and ImmuneOncia Expand Partnership
Sign multi-product development and manufacturing agreement for five candidate molecules.Contract Pharma Staff 07.15.20
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Information Technology | Validation
Samsung Biologics Achieves ISO27001 Certification
Becomes first CDMO to receive highly touted recognition for information security management.11.15.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Samsung Biologics and Ichnos Sciences Ink Mfg. Deal
Samsung to manufacture drug substance for ISB 830 Phase 3 clinical trials and for potential future global commercial supply upon regulatory approval.11.05.19
-
Bio News | Breaking News | Facilities | Industry News
Samsung BioLogics Expands Biomanufacturing Capabilities
Implements large scale N-1 perfusion for commercial application08.12.19
-
Bio News | Breaking News | cGMP Manufacture | Collaborations & Alliances | Industry News
Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal
The CDMO will also produce UCB's anti-tau candidate to treat progressive supranuclear palsy07.31.19
-
-
Promotions & Moves
Pii Appoints Business Executives
Ideus, Grellner and McFarlane to head market engagement and business management activities07.02.19
-
Bio News | Biologics, Proteins, Vaccines | cGMP Manufacture | Clinical Trial Materials | Industry News
Samsung BioLogics, GI Innovation Ink Second Contract
Samsung BioLogics will provide contract services from the development of cell lines to the production of Phase I drug substances for GI05.03.19
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Clinical Trial Materials | Industry News | Scale-up/Technology Transfer
Samsung BioLogics, CytoDyn Enter Mfg. Agreement
Will make $1 billion worth of Leronlimab to meet expected demand for future revenues post-approval04.02.19
-
Lyophilization
-
Breaking News | Drug Development | Industry News
Samsung BioLogics, Biogen Conclude Asset Transfer
Transfers shares of Samsung Bioepis for $677 million11.06.18
-
Bio News | Breaking News | cGMP Manufacture | Facilities | Industry News | Validation
Samsung BioLogics' Plant 3 Starts Production
World’s largest single bio manufacturing plant is cGMP ready and started production (OOF, out of freezing) after validation10.01.18
-
Collaborations & Alliances | Industry News | Information Technology
Samsung BioLogics Selects Veeva Vault QualityDocs
To provide transparency into content status and processes for internal and external users, partners, and suppliers worldwide07.23.18
-
cGMP Manufacture | Industry News | Regulatory Affairs
Samsung BioLogics Licensed by Health Canada
To manufacture a monoclonal antibody drug substance at its first plant06.21.18
-
cGMP Manufacture | Drug Development | Facilities | Fill/Finish | Formulation Development
Samsung BioLogics Details End-To-End Services
CDO Team Lead at Samsung BioLogics, Eun Young Yang, shares insight on the company’s one-stop CDMO offerings
-
cGMP Manufacture | Industry News | Inspections
Samsung BioLogics Receives Additional FDA Approval
Gains third approval for Plant 2 in 26 months05.24.18
-
Bio News | Breaking News | Industry News | QA/QC | Regulatory Affairs | Validation
Samsung BioLogics Achieves Regulatory Milestone
Becomes first in South Korean pharma industry to achieve ISO 22301 certificate04.27.18
-
Biologics, Proteins, Vaccines | Biosimilars
Contract BioManufacturing in China: Creating a New Segment
An up-close look at China’s growing market for CMO services.Vicky Qing Xia and Leo Cai Yang, BioPlan Associates 04.10.18
-
Pharma Year 2017 in Review
CDMOs grow faster than the Pharma market.Christoph Bieri, Managing Partner, Kurmann Partners 03.09.18
-
Biologics, Proteins, Vaccines | cGMP Manufacture | Industry News
Samsung BioLogics Wins First Contract for Plant 3 Facility
Facility has 180,000 liters total capacity and is expected to be cGMP operational by 4Q1802.22.18
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | cGMP Manufacture | Industry News
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Inspections | Validation
VIDEO: Samsung BioLogics Receives EMA Approval for its Second Plant
Licensed by EMA for its second plant only two months after FDA approval12.13.17
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Facilities | Industry News | Validation
FDA Approves Samsung Biologics’ Second Plant
Contract manufacturer gets the ‘green light’ for commercial production at 152,000-liter plant10.16.17
-
Welcome to the 28th CPhI Worldwide!
The world of pharma returns to FrankfurtOrhan Caglayan, UBM 10.11.17
-
Biologics, Proteins, Vaccines
CEO Spotlight: Samsung Biologics
A conversation with Samung Biologics CEO, Dr. TH KimTim Wright, Contract Pharma 10.11.17
-
Bio News | Breaking News | cGMP Manufacture | Industry News
Sun Pharma & Samsung BioLogics Ink Mfg. Deal
Enter $50 million strategic manufacturing tie-up for Tildrakizumab07.05.17
-
Drug Development | Inspections | Supply Chain
Why Regulatory Changes Matter in APAC
FDA is increasing inspections in Asia as more and more generics are being made thereWarren Perry, Dassault Systu00e8mes BIOVIA 09.11.15
-
Biosimilars
-
Biologics, Proteins, Vaccines | Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
BMS, Samsung BioLogics Expand Manufacturing Pact
Samsung to manufacture several BMS biologics at Incheon site04.23.14
-
Biologics, Proteins, Vaccines | Breaking News | Capsules | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Industry News | Lyophilization | Process Development
Samsung BioLogics, Roche Sign Strategic Manufacturing Pact
To manufacture Roche’s commercial biologics at Incheon facilities10.22.13
-
Bio News | Biologics, Proteins, Vaccines | Breaking News | Capsules | Collaborations & Alliances | Extractables and Leachables | Facilities | Fill/Finish | GMPs/GCPs | Lyophilization | Process Development | Scale-up/Technology Transfer | Validation
-
Biosimilars | Clinical Trials | Drug Development | Formulation Development | Process Development | Supply Chain | Toxicology | Vials
Biosimilars Update
When will we see legal generics of top biopharmaceuticals?Gil Roth, Contract Pharma 04.03.13
-
Biosimilars
-
Bio News | Biologics, Proteins, Vaccines | Biosimilars | Breaking News | Collaborations & Alliances | R&D
Samsung, Biogen Advance Biosimilars Joint Venture
Establish Samsung Bioepis, begin Korea R&D siteGil Roth 02.28.12
-
Biosimilars | Breaking News
